The effect of carvedilol on metabolic parameters in patients with metabolic syndrome

International Heart Journal

Volumn 47, Issue 3, 2006, Pages 421-430

  Uzunlulu, Mehmet ^a   Oguz, Aytekin ^a   Yorulmaz, Elif ^a  

^a Goztepe Training and Research Hospital ^*  (Turkey)

Author keywords

Atenolol; Carvedilol; Doxazosin; Hypertension; Metabolic syndrome

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; ATENOLOL; CARVEDILOL; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTHROPOMETRY; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARBAZOLES; CHOLESTEROL, HDL; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33746132286     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.421     Document Type: Article

References (27)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607. (Review)
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-28. (Review)
3. Pollare T, Lithell H, Selinus I. Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-20.
4. 2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665-71.
5. Dahlof B, Devereux RB, Kjeldsen SF, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
6. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-9.
7. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents? Am J Hypertens 1998; 11: 1258-65. (Review)
8. Messerli FH, Grossman E. β-blockers in hypertension: is carvedilol different? Am J Cardiol 2004; 93 (suppl): 7B-12. (Review)
9. Ho WJ, Tsay PK, Chu PH, Chang CJ, Kuo CT, Chen WJ. Predictors of stable outcome in treating chronic heart failure patients with carvedilol. Jpn Heart J 2004; 45: 823-32.
10. Bell DS. Advantages of a third-generation β-blocker in patients with diabetes mellitus. Am J Cardiol 2004; 93 (suppl): 49B-52. (Review)
11. Poole-Wilson PA. Commentary on the Carvedilol or Metoprolol European Trial (COMET). Am J Cardiol 2004; 93 (suppl): 40B-2.
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
13. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997; 20:1744-66. (Review)
14. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996, 19: 1138-41.
15. Giugliano D, Acampora, R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med 1997; 126:955-9.
16. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol. vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004; 292: 2227-36.
17. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993; 45: 95-100.
18. Seguchi H, Nakamura H, Aosaki N, Homma Y, Mikami Y, Takahashi S. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol. 1990; 38: S139-42.
19. Goto Y, Tamachi H, Fusegawa Y, et al. Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc; Pharmacol 1991; 18: S45-50.
20. Gonzalez Maqueda I. Adrenoreceptors endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994; 5:909-18.
21. Oda E, Hatada K, Kimura, J, Aizawa Y, Thanikachalam PV, Watanabe K. Relationships between serum unsaturated fatty acids and coronary risk factors: negative relations between nervonic acid and obesity-related risk factors. Int Heart J 2005; 46:975-85.
22. Gang A, Bantle JP, Henry, RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994; 271: 1421-8.
23. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA 2003; 290: 2322-4.
24. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-71.
25. Kontush A, de Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterized by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005; 182: 277-85.
26. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa, J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116: 460-5.
27. Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300:902-3.